Condition

Elevated Intraocular Pressure

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 5 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials5

Recruiting0

Common interventions8

Lead sponsors shown5

Clinical trials

5 shown

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular PressureNCT05165290 · 2021-11-29

UNKNOWN

Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by LatanoprostNCT01896180 · 2013-07-01

COMPLETED

A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)NCT00902200 · 2009-05-01

COMPLETED

Intraocular Pressure Accuracy and Variability of the Barraquer TonometerNCT00409669 · 2006-11-01

UNKNOWN

Acupuncture for Elevated Intraocular PressureNCT00307918 · 2006-05-01

TERMINATED

Common interventions

acupunctureDEVICE1 ALZ-1101DRUG1 AR-12286DRUG1 AR-12286 vehicleDRUG1 Barraquer tonometerDEVICE1 LatanoprostDRUG1 Latanoprost ophthalmic solution, 0.005%DRUG1 TC-002 latanoprost ophthalmic solution, 0.005%DRUG1

Leading sponsors

Aerie Pharmaceuticals 1 Alleanza Pharmaceuticals, Inc. 1 Barnes Retina Institute 1 Shaare Zedek Medical Center 1 TearClear Corp 1

Trial status mix

COMPLETED2

UNKNOWN2

TERMINATED1

Phase mix

PHASE22

PHASE32

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.